Bamco Inc. NY Boosts Stake in Exact Sciences Corporation

The investment firm increased its position in the medical research company by nearly 15% in the third quarter.

Mar. 15, 2026 at 8:34am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, an investment management firm, boosted its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 14.9% in the third quarter of 2026. The firm now owns approximately 2.14 million shares of the medical research company, or around 1.13% of Exact Sciences' outstanding stock.

Why it matters

This increase in Bamco's position in Exact Sciences suggests the investment firm sees long-term potential in the company, which develops innovative cancer screening and diagnostic tests. As a major shareholder, Bamco's actions can influence the company's strategic direction and investor sentiment.

The details

According to a recent SEC filing, Bamco Inc. NY purchased an additional 277,709 shares of Exact Sciences in the third quarter, bringing its total position to 2,139,050 shares. This represents approximately 1.13% of the medical research company's outstanding stock. Exact Sciences is known for its flagship product, the Cologuard stool-based DNA screening test for colorectal cancer.

  • Bamco Inc. NY increased its stake in Exact Sciences in the third quarter of 2026.

The players

Bamco Inc. NY

An investment management firm that has increased its position in Exact Sciences Corporation.

Exact Sciences Corporation

A medical research company that develops innovative cancer screening and diagnostic tests, including the Cologuard colorectal cancer screening product.

Got photos? Submit your photos here. ›

The takeaway

Bamco Inc. NY's increased stake in Exact Sciences suggests the investment firm sees long-term growth potential in the medical research company and its cancer screening products. This could signal positive sentiment among major investors about Exact Sciences' future prospects.